Welcome to our dedicated page for Ani Pharmaceutic SEC filings (Ticker: ANIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for ANI Pharmaceuticals, Inc. (Nasdaq: ANIP), a diversified biopharmaceutical company focused on rare disease, generics, and branded therapeutics. Through these filings, investors can review how ANI reports its financial results, capital structure changes, and other material events related to its Rare Disease, Generics, and Brands businesses.
ANI frequently files Form 8-K current reports to disclose quarterly and year-to-date financial results, updated investor presentations, and other significant developments. For example, recent 8-K filings reference press releases announcing results for specific quarters, updated guidance, and the publication of investor presentations that describe the company’s strategy, segment performance, and focus on products such as Purified Cortrophin Gel and ILUVIEN. Other 8-K filings discuss matters like the conversion of Series A Convertible Preferred Stock into common shares and updates on litigation outcomes.
In addition to 8-Ks, investors can use this filings page to locate ANI’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which provide more detailed discussions of segment results, risk factors, product portfolios, and the company’s rare disease strategy. These periodic reports elaborate on how ANI’s Rare Disease, Generics, and Brands businesses contribute to overall performance and outline risks related to manufacturing, regulatory approvals, competition, and market conditions.
Filings related to equity and capital structure are also important for ANIP. For instance, the company has reported on the issuance and subsequent conversion of Series A Convertible Preferred Stock, including dividend terms and conversion conditions, and on the issuance of common shares upon conversion under exemptions from registration. Such disclosures help investors understand changes in outstanding securities and potential dilution.
Stock Titan enhances this information by offering AI-powered summaries of ANI’s key filings. These summaries highlight the main points from lengthy documents, such as revenue trends, segment performance, major product updates, and notable legal or corporate events. Users can quickly scan 10-Ks, 10-Qs, and 8-Ks, and then dive into the full text on EDGAR for deeper analysis. The filings page also surfaces information relevant to insider and security-holder activity where reported, enabling a more complete view of ANI Pharmaceuticals’ regulatory and financial disclosures.
ANI Pharmaceuticals SVP Krista Davis reported a tax-withholding share disposition. On February 11, 2026, 3,017 shares of ANI Pharmaceuticals common stock were disposed of at $76.25 per share as a tax-withholding disposition related to equity compensation.
The footnote explains that these shares were withheld for tax purposes in connection with the vesting of 8,104 performance stock units, a grant originally reported on April 6, 2023. After this transaction, Davis directly owned 55,547 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals SVP Chad Gassert reported a tax-related share withholding on company stock. On February 11, 2026, 4,269 shares of ANI Pharmaceuticals common stock were disposed of at $76.25 per share to cover tax obligations tied to the vesting of 11,578 performance stock units previously granted.
After this tax-withholding disposition, Gassert directly beneficially owned 69,346 shares of common stock. He also indirectly beneficially owned an additional 158,490 shares held by Chali Properties LLC, over which he holds voting and dispositive power.
ANI Pharmaceuticals senior vice president Ori Gutwerg reported a tax-related share disposition linked to equity vesting. On 02/11/2026, 4,267 shares of common stock were disposed of at $76.25 per share to cover tax withholding in connection with the vesting of 11,578 performance stock units.
Following this tax-withholding transaction, Gutwerg directly beneficially owned 79,757 shares of ANI Pharmaceuticals common stock. The filing characterizes the transaction as exempt under Rule 16(b)-3 because it relates to equity compensation vesting rather than an open-market trade.
Lalwani Nikhil reported disposition transactions in a Form 4 filing for ANIP. The filing lists transactions totaling 30,659 shares at a weighted average price of $76.25 per share. Following the reported transactions, holdings were 380,560 shares.
ANI Pharmaceuticals executive Christopher Mutz, Head of Rare Disease, reported a tax-withholding disposition of company stock related to equity compensation. On February 11, 2026, 4,546 shares of ANI Pharmaceuticals common stock were withheld at $76.25 per share to cover taxes.
This withholding was tied to the vesting of 11,578 performance stock units previously granted on April 6, 2023 and is exempt under Rule 16(b)-3. After this transaction, Mutz directly holds 102,771 shares of ANI Pharmaceuticals common stock.
Rowland Thomas Andrew reported disposition transactions in a Form 4 filing for ANIP. The filing lists transactions totaling 1,762 shares at a weighted average price of $76.25 per share. Following the reported transactions, holdings were 39,160 shares.
Shanmugam Muthusamy reported disposition transactions in a Form 4 filing for ANIP. The filing lists transactions totaling 2,898 shares at a weighted average price of $76.25 per share. Following the reported transactions, holdings were 89,940 shares.
ANI Pharmaceuticals executive Meredith W. Cook, Senior Vice President, General Counsel and Secretary, reported a small open-market sale of company common stock. On January 13, 2026, she sold 500 shares of ANI Pharmaceuticals common stock at a price of $84.33 per share, as disclosed in a Form 4 insider trading report.
After this transaction, Cook directly beneficially owned 74,374 shares of ANI Pharmaceuticals common stock. The filing notes that this sale was carried out under a pre-established Rule 10b5-1 trading plan that she adopted on September 15, 2025, indicating the trades were scheduled in advance rather than timed at her discretion.
ANI Pharmaceuticals, Inc. reported that it has issued a press release with select preliminary unaudited financial results for the fourth quarter and full fiscal year ended December 31, 2025, along with preliminary 2026 financial guidance. These figures are based on management estimates, have not been audited or reviewed by the company’s independent registered public accounting firm, and may change, potentially in a material way.
The company also noted that President & CEO Nikhil Lalwani will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, with an accompanying investor presentation furnished as an exhibit. The preliminary results and guidance, as well as the presentation materials, are provided as furnished information and are not deemed filed for liability purposes under the securities laws.
ANI Pharmaceuticals reported an insider stock sale by senior vice president, general counsel and secretary Meredith W. Cook. On December 12, 2025, she sold 400 shares of the companys common stock at $82.32 per share.
After this transaction, Cook directly beneficially owned 74,874 ANI Pharmaceuticals shares. The disclosure states that the sale was carried out under a Rule 10b5-1 trading plan that she adopted on September 17, 2024, indicating the trade was made pursuant to a pre-established plan.